Abstract 382P
Background
Much of the inter-individual differences in the regulation, expression, and activity of drug metabolizing enzymes genes might be crucial factors in defining cancer susceptibility, as well as in determining the efficacy of drugs. Cytochrome P450 (CYP) family of enzymes are the most important drug metabolizing enzymes involved in the metabolism of widely used drugs including anticancer drugs like tamoxifen and cyclophosphamide. Therefore, present study was undertaken to investigate the association of variant genotypes of CYP2C9, CYP2C19 & CYP2D6 with the treatment response (personalized medicine approach) in Head and Neck cancer cases receiving chemotherapy or combination of chemo- and radiotherapy.
Methods
800 patients suffering from Head & Neck cancer and equal number of age matched controls were included in the study. Genomic DNA was isolated from the blood samples and CYP2C9, CYP2C19 & CYP2D6 genotypes were determined in genomic DNA by PCR based RFLP. Follow-up carried out to correlate the association (if any) in between variants and treatment outcome.
Results
Amongst heterozygous and homozygous variants of CYP2C9*2/*3; CYP2C19*2 /*3 (i.e. CYP2C9*1/*2, CYP2C9*1/*3, CYP2C19*1/*2 & CYP2C19*1/*3) and CYP2D6*4/*10, a high percentage of cases was encountered as non-responders and had toxicities like nausea, vomiting, dizziness etc., as compared to the responders in the same category. In the follow-up study, it was found that a significantly higher number of non-responders (p-value<0.05) were encountered in the cases carrying variant genotypes of either of CYP2C9*2, CYP2C9*3, CYP2C9*2/*3, CYP2C19*2, CYP2C19*3, CYP2C19*2/*3, CYP2D6*4 and CYP2D6*10.
Conclusions
It was demonstrated that CYP2C9, CYP2C19 and CYP2D6 variants modify the treatment outcome in cases receiving combination of radio-chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Government of India.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
164P - Multi-centered phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502)
Presenter: Yusuke Sasaki
Session: Poster display session
Resources:
Abstract
165P - Lenvatinib treatment for advanced hepatocellular carcinoma: The relationship between efficacy and safety
Presenter: Takayoshi Oikawa
Session: Poster display session
Resources:
Abstract
166P - The comparison between UGT1A1 single heterozygous and wild type regarding the clinical outcomes of fixed dose irinotecan monotherapy for advanced gastric cancer: Multicenter retrospective study
Presenter: Takahide Sasaki
Session: Poster display session
Resources:
Abstract
167P - Prognostic impact of the C-reactive protein/albumin ratio in advanced pancreatic cancer treated with GEM plus nab-PTX or FOLFIRINOX: Based on the results of a multicenter retrospective study (the NAPOLEON study)
Presenter: Akitaka Makiyama
Session: Poster display session
Resources:
Abstract
168P - A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of Glasgow Prognostic Score (GPS)
Presenter: Takuya Honda
Session: Poster display session
Resources:
Abstract
169P - M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signalling pathways
Presenter: Yizhuo Wang
Session: Poster display session
Resources:
Abstract
170P - Surgery alone versus surgery combined with Chemotherapy: Survival patterns among patients with fibrolamellar hepatocellular carcinoma
Presenter: Yasmine Ashraf
Session: Poster display session
Resources:
Abstract
171P - The clinical value of prognostic nutritional index in patients with anastomotic leakage after minimally invasive esophagectomy
Presenter: Yan Wang
Session: Poster display session
Resources:
Abstract
172P - Preoperative neutrophil‐to‐lymphocyte ratio (NLR) predicts recurrence after surgery in patient with pancreatic neuroendocrine neoplasm (PanNEN)
Presenter: Takayuki Miura
Session: Poster display session
Resources:
Abstract
173P - Cancer stem-like phenotypes including immune surveillance and its responsible genes in induced liver cancer stem-like cells
Presenter: Ryouichi Tsunedomi
Session: Poster display session
Resources:
Abstract